HHS to invest in domestic production of essential medical supplies
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Headline
President Trump April 9 announced that reciprocal tariffs that went into effect after midnight for certain nations will be paused for 90 days, while tariffs…
Headline
The Food and Drug Administration March 14 released a notice on a nationwide shortage of hemodialysis tubes expected to last through early fall. On Jan. 8, B.…
Headline
The AHA late Feb. 4 told the administration that its current and proposed tariffs on Canada, Mexico and China may jeopardize the availability of vital…
Headline
Baxter Jan. 28 announced that IV solutions production has been restarted on all manufacturing lines at its North Carolina site impacted by Hurricane Helene in…
Headline
Baxter notified customers on Jan. 22 that allocations for two sodium chloride IV solutions have been increased to 100%. According to Baxter, the products will…
Headline
After incurring damage from Hurricane Helene on Sept. 27, Baxter reports that as of Dec. 19, nearly all of its manufacturing lines in its North Cove, N.C…